Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP

(marketscreener.com) First-ever interventional trial for patients with ALSP, a rare and rapidly progressing neurological disease with significant unmet medical needCAMBRIDGE, Mass., Dec. 14, 2022 -- Vigil Neuroscience, Inc. , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases,...https://www.marketscreener.com/quote/stock/VIGIL-NEUROSCIENCE-INC-131408792/news/Vigil-Neuroscience-Announces-First-Patient-Dosed-in-the-IGNITE-Phase-2-Clinical-Trial-to-Evaluate-VG-42549363/?utm_medium=RSS&utm_content=20221214